Literature DB >> 10076128

Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model.

A Nagler1, O Genina, I Lavelin, M Ohana, M Pines.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the effects of halofuginone-a specific inhibitor of collagen type I synthesis-in preventing uterine horn adhesion formation in rats. STUDY
DESIGN: Adhesions were induced by scraping the rat uterine horns until capillary bleeding occurred. Halofuginone was either injected intraperitoneally or administered orally. The number and severity of the adhesions were scored. Collagen alpha1(I) gene expression was evaluated by in situ hybridization; total collagen was estimated by sirius red staining. Collagen synthesis in response to halofuginone was evaluated in cells cultured from the adhesions.
RESULTS: Regardless of the administration procedure, halofuginone reduced significantly the number and severity of the adhesions in a dose-dependent manner. Halofuginone prevented the increase in collagen alpha1(I) gene expression observed in the rats that underwent this procedure, thus affecting only the newly synthesized collagen but not the resident collagen. In cells derived from rat uterine horn adhesions, halofuginone induced dose-dependent inhibition of collagen synthesis.
CONCLUSIONS: Upregulation of collagen synthesis appears to play a critical role in the pathophysiologic mechanism of adhesion formation. Halofuginone could be used as an important means of understanding the role of collagen in adhesion formation and might become a novel and promising antifibrotic agent for preventing adhesion formation after pelvic surgery.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10076128     DOI: 10.1016/s0002-9378(99)70254-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis.

Authors:  R Abramovitch; H Dafni; M Neeman; A Nagler; M Pines
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

Review 2.  Adhesive small bowel obstruction: epidemiology, biology and prevention.

Authors:  Jo-Anne P Attard; Anthony R MacLean
Journal:  Can J Surg       Date:  2007-08       Impact factor: 2.089

3.  Efficacy of topical halofuginone in myringotomy patency.

Authors:  Taner Ozdemir; Hakan Cincik; Salim Dogru; I Engin Cekin; S Arif Ulubil; Atila Gungor
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06-24       Impact factor: 2.503

4.  Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib.

Authors:  Arin K Greene; Ian P J Alwayn; Vania Nose; Evelyn Flynn; David Sampson; David Zurakowski; Judah Folkman; Mark Puder
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

Review 5.  Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract.

Authors:  Mark Pines
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

6.  Preliminary design of a new degradable medical device to prevent the formation and recurrence of intrauterine adhesions.

Authors:  Salome Leprince; Stéphanie Huberlant; Lucie Allegre; Sophie Warembourg; Isabelle Leteuff; Audrey Bethry; Cedric Paniagua; Hubert Taillades; Renaud De Tayrac; Jean Coudane; Vincent Letouzey; Xavier Garric
Journal:  Commun Biol       Date:  2019-05-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.